Lars Lannfelt

Comparing binding characteristics to Aβ of lecanemab, aducanumab & gantenerumab 4:01
Comparing binding characteristics to Aβ of lecanemab, aducanumab & gantenerumab
Lars Lannfelt • 16 Mar 2022
Lecanemab path to approval 1:23
Lecanemab path to approval
Lars Lannfelt • 16 Mar 2022
The development of lecanemab & rationale behind its unique binding profile 6:01
The development of lecanemab & rationale behind its unique binding profile
Lars Lannfelt • 17 Mar 2022
The content of VJDementia is intended for healthcare professionals